Fördjupning

Det finns en lång rad kliniska studier gjorda med bakteriestammen under det nuvarande namnet Bifidobacterium longum 35624® samt det tidigare Bifidobakterium infantis 35624®. Besök gärna National Library of Medicines hemsida för en uppdaterad lista: https://www.ncbi.nlm.nih.gov/pubmed, sökord ”Bifidobacterium 35624”. Nedan återfinns några exempel på intressanta studier från denna lista.

Symtomlindring

Two randomized, controlled trials have validated its efficacy for treating both individual and global IBS symptoms without evidence to suggest an increase in adverse events. B. infantis 35624 appears safe and effective for the treatment of IBS.

Brenner D. M. mfl. Rev Gastroenterol Disord. 2009 Winter;9(1):7-15.

Thirty days of treatment with B. longum 35624 reduces disease severity and improves the quality of life of patients with IBS, particularly those with the most severe forms of IBS.

• Sabaté J-M mfl. World J Gastroenterol. 2022 Feb 21;28(7):732-744.
• B. infantis 35624 is a probiotic that specifically relieves many of the symptoms of IBS
• Whorewell P. J. mfl. Am J Gastroenterol. 2006 Jul;101(7):1581-90.

B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.

O’Mahony L. mfl. Gastroenterology. 2005 Mar;128(3):541-51.

Bakteriestammens ursprung och mekanik

Bifidobacterium longum 35624® är en unik stam som finns naturligt i vår tarmflora.

Kiely B, Inventor. Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection. 2018.

The bifidobacterium longum 35624® culture transits in high numbers through the human gut

• Healy S. mfl. (2017) Gut 66, A25.

Faecal analysis demonstrated that the strain had established itself in the colon

• Von Wright A. mfl. (2002) International Dairy Journal 12, 197–200.
• Bernet M.F. mfl. (1993) Applied & Environmental Microbiology 59, 4121–8.

Guidelines/riktlinjer

I riktlinjerna från World Gastroenterology Organisation (WGO, 2015) rapporteras Bifidobacterium longum 35624® ha den bästa evidensbasen för effekt vid IBS3.

Quigley EM, Fried M, Gwee KA, et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704-713

The European Society of Primary Care Gastroenterology (ESPCG, 2018) slår samstämmigt fast att Bifidobacterium longum 35624® hjälper till att lindra den generella symtombilden hos vissa patienter med IBS. [Evidensgrad: Hög]4

Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. Alimentary pharmacology & therapeutics. 2018;47(8):1054-1070

National Institute for Health and Care Excellence. Clinical guideline 61: Irritable bowel syndrome in adults: diagnosis and management. https://www.nice.org.uk/guidance/cg61/chapter/Introduction. Accessed 06.01.22.